Trius Therapeutics Inc. (TSRX) posted fourth-quarter net loss of $14.2 million or $0.36 per share, wider than $12.5 million or $0.44 per share in the comparable quarter last year.
On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share. Analysts' estimates typically exclude special items.
Total revenues for the quarter were $5.16 million, compared with $5.00 million in the prior year quarter, while nine analysts had consensus revenue estimate of $4.60 million for the quarter.
For comments and feedback: editorial@rttnews.com